Watson Pharmaceuticals Inc, AstraZeneca cardiovascular news

AstraZeneca filed suit in the U.S. District Court for the District of Delaware alleging that Watson's NDA submission for rosuvastatin zinc tablets infringes AstraZeneca's U.S. Patent No. RE37,314 covering cardiovascular drug Crestor rosuvastatin. Watson submitted the NDA to FDA for rosuvastatin under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from scientific literature or from previously approved products. AstraZeneca is seeking to prevent the marketing of the generic prior to the patent expiration. ...